| Grant number: | 23/12810-9 |
| Support Opportunities: | Scholarships in Brazil - Post-Doctoral |
| Start date: | December 01, 2023 |
| End date: | November 30, 2025 |
| Field of knowledge: | Health Sciences - Medicine |
| Principal Investigator: | Carmen Silvia Passos Lima |
| Grantee: | Juliana Carron |
| Host Institution: | Centro de Hematologia e Hemoterapia (HEMOCENTRO). Universidade Estadual de Campinas (UNICAMP). Campinas , SP, Brazil |
| Associated research grant: | 21/10265-8 - Cancer Theranostics Innovation Center (CancerThera), AP.CEPID |
Abstract Glioblastoma multiforme (GBM) is the most aggressive brain tumor, with high morbidity and mortality rates. The treatment for patients with GBM is surgical resection of the tumor followed by temozolomide chemoradiation, but the median overall survival is only 14 months. The epidermal growth factor receptor (EGFR) overexpression in GBM drives cell invasion and tumor progression, but results of treatment with EGFR tyrosine kinase inhibitors, such as gefitinib, are disappointing. Integrin, a cell surface adhesion membrane receptor, is overexpressed in GBM and tumor-relevant blood vessels. It has a high affinity for the protein components of the extracellular matrix, and plays important roles in cell invasion and motility, allowing for crosstalk between the cell and the surrounding stroma as well as with adjacent vascular growth factor receptors. Thus, integrin is a potential therapeutic target for antitumor products. The assessment of therapy response and tumor progression or relapse by conventional imaging tests is another problem, since false positive and false negative results are frequent during follow-up of patients with GBM. Radiolabeled peptides have gained prominence in Nuclear Medicine and Oncology because they can be used for obtaining in vivo images and for treatment of patients with tumors with overexpression of specific receptors. Recently, two peptides with high affinity for integrin, GRGDYV and GRGDHV, were labeled with iodine-131 (131I) and technetium-99m-tricarbonyl complex [99mTc] [Tc(CO)3], and they were described as promising agents for future clinical application in GBM. The current project will test a radiolabeled anti-integrin peptide modified by conventional chelator in preclinical models, seeking subsidies for the development of new forms of diagnosis and treatment for GBM. | |
| News published in Agência FAPESP Newsletter about the scholarship: | |
| More itemsLess items | |
| TITULO | |
| Articles published in other media outlets ( ): | |
| More itemsLess items | |
| VEICULO: TITULO (DATA) | |
| VEICULO: TITULO (DATA) | |